Almirall’s Skin Academy Spotlights Advances in Dermatology, Patient Outcomes

Event summary

  • Almirall hosted its 17th Skin Academy on March 23, 2026, with 800 participants.
  • Focus areas included inflammatory skin diseases, skin cancer, and holistic care in dermatology.
  • Key discussions centered on atopic dermatitis, psoriasis, and actinic keratosis.
  • Patient-reported outcomes and psycho-dermatology were highlighted as critical components of treatment.
  • Almirall emphasized the need for innovative assessment tools for facial and neck atopic dermatitis.

The big picture

Almirall’s Skin Academy underscores the company’s strategic focus on advancing dermatological science and patient care. The event highlights the growing importance of holistic treatment approaches and targeted therapies in addressing unmet needs in inflammatory skin diseases. With a revenue of €1114.5 million in 2025, Almirall is positioning itself as a key player in the biopharmaceutical sector, leveraging scientific collaboration to drive innovation.

What we're watching

Innovation Pipeline
How Almirall’s focus on targeted therapies for atopic dermatitis and psoriasis will impact its product pipeline.
Patient-Centric Approach
Whether the emphasis on patient-reported outcomes and psycho-dermatology will drive better treatment adherence and outcomes.
Market Positioning
The pace at which Almirall can differentiate itself in the competitive dermatology market through scientific leadership.